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 ABSTRACT
   Objective      To evaluate the safety, tolerability, 
pharmacokinetic and pharmacodynamic proﬁ  les of 
mavrilimumab, a human monoclonal antibody targeting 
the granulocyte-macrophage colony-stimulating factor 
receptor-α, in subjects with rheumatoid arthritis (RA).   
  Methods      A randomised, double-blind, placebo-
controlled, dose-escalating phase I study in subjects 
with RA who received stable methotrexate treatment 
for ≥3 months before enrolment. Subjects received 
single intravenous escalating doses of mavrilimumab 
(0.01–10.0 mg/kg) or placebo.   
  Results      32 subjects were enrolled in this study 
(1 unblinded subject at 0.01 mg/kg and another at 
0.03 mg/kg were followed by ﬁ  ve sequential double-
blinded cohorts, n=6 each, treated with 0.1, 0.3, 1.0, 3.0 
and 10.0 mg/kg, respectively). Adverse events were mild 
or moderate and were reported with similar frequency 
across all treatment cohorts. One subject (10.0 mg/kg) 
experienced moderate face and neck urticaria during 
infusion that resolved with symptomatic treatment. 
Systemic clearance of mavrilimumab approached that of 
endogenous IgG at doses >1.0 mg/kg; pharmacodynamic 
activity was conﬁ  rmed in the 1.0 and 3.0 mg/kg cohorts 
by suppression of suppressor of cytokine signalling 
3 mRNA transcripts. In exploratory analyses, reductions 
of acute phase reactants were observed in subjects with 
elevated C-reactive protein (>5 mg/l) and erythrocyte 
sedimentation rate (≥20.0 mm/h) at baseline. No 
signiﬁ  cant change in Disease Activity Score 28-joint 
assessment (DAS28) was seen in any of the cohorts. 
In mavrilimumab-treated subjects (n=15) with baseline 
DAS28 >3.2, mean disease activity (DAS28) was 
signiﬁ  cantly reduced at 4 weeks.   
  Conclusion      In this ﬁ  rst-in-human study, mavrilimumab 
showed preliminary evidence of pharmacodynamic 
activity. Importantly, the safety and pharmacokinetic 
proﬁ  les of mavrilimumab support further clinical 
studies in RA. 
 Trial  registration  number:  NCT00771420.      
  INTRODUCTION 
  Biological treatments such as tumour necrosis factor 
(TNF) inhibitors have revolutionised rheumatoid 
arthritis (RA) treatment over the past decade.  1    –    3   
However, new treatments are needed for the sig-
niﬁ  cant proportion of subjects who fail to achieve 
the minimum improvement criteria  4   or experience 
signiﬁ   cant toxicities (eg, serious and opportunis-
tic infection,  5   tachyphylaxis or development of 
resistance) and to provide more subjects with a 
higher likelihood of achieving disease remission.  6   
While many components of the immune system 
contribute to the development and progression of 
RA, it has been shown that treatments reducing 
CD68+ macrophage numbers in the sublining of 
the pannus lead to a reduction in disease activity.  7   
Therefore, molecules directly targeting macrophage 
function may prove beneﬁ  cial in these refractory 
subjects. 
  Granulocyte-macrophage colony-stimulating 
factor (GM-CSF) is a soluble cytokine that pro-
motes the generation, survival and activation of 
cells from the myeloid compartment, notably 
neutrophils, eosinophils and macrophages.  8    –    11   
GM-CSF also regulates numerous functions of 
mature tissue macrophages, including a number 
of host defence functions—for example, cell adhe-
sion, expression of pathogen recognition receptors 
and proinﬂ  ammatory cytokines (TNFα, interleu-
kin (IL)-12, IL-18, IL-6, monocyte chemotactic 
protein 1 and M-CSF), phagocytosis and micro-
bial killing.  12   Furthermore, it is well documented 
that GM-CSF signalling is critical in maintaining 
the ability of pulmonary alveolar macrophages to 
clear surfactant lipids and proteins from the lung 
surface. For this reason, safety monitoring in this 
study included a number of tests and assessments 
to ensure an appropriate evaluation of potential 
lung toxicities. 
  Raised levels of GM-CSF and its receptor in the 
synovial ﬂ  uid and plasma of subjects with RA and 
overexpression of GM-CSF receptor within cells of 
the synovial tissue and on circulating mononuclear 
cells, as well as the production by chondrocytes,  13    –
    16   suggest a potential role for this cytokine in RA. 
Preclinical models have further supported this 
hypothesis; overexpression of GM-CSF resulted in 
accelerated and more severe inﬂ  ammation than in 
control mice,  17   and direct injection of recombinant 
GM-CSF into a mouse model of arthritis exacer-
bated the disease.  18     19   Conversely, a deﬁ  ciency in 
GM-CSF was shown to be protective in several 
models of induced arthritis.  20    –    23   In isolated obser-
vations in humans, recombinant GM-CSF admin-
istered to subjects undergoing treatment to resolve 
neutropenia in Felty’s syndrome  24     25   or after che-
motherapy  25   has also promoted arthritic ﬂ  ares. 
Taken together, these data suggest that GM-CSF 
is a key player in arthritis and that blocking this 
  pathway may provide beneﬁ  t. 
  Additional data are published    ▶
online only. To view these ﬁ  les 
please visit the journal online at 
(http://ard.bmj.com).   
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  GM-CSF receptors are heterodimers consisting of a ligand-
speciﬁ  c α-subunit (GM-CSFR-α) and a β-chain subunit that is 
shared with IL-3 and IL-5 receptor.  26     27   GM-CSFR-α binds to 
the cytokine with high speciﬁ  city and low afﬁ  nity, whereas the 
common β subunit is responsible for JAK2/STAT3/STAT5 sig-
nalling.  26     28     29   Mavrilimumab, formerly known as CAM-3001, is 
a novel high-afﬁ  nity human monoclonal IgG4 antibody (  isolated 
by phage display) against GM-CSFR-α that is a competitive 
antagonist of GM-CSF signalling. 
  Currently, no data exist on targeting the innate arm of the 
immune system via the GM-CSF pathway in RA. We report the 
results of a ﬁ  rst-in-human study evaluating the safety, tolerabil-
ity, pharmacokinetic and pharmacodynamic proﬁ  les of single 
ascending intravenous doses of mavrilimumab in adult subjects 
with mild to moderate RA.   
  SUBJECTS  AND  METHODS 
  This study was conducted in accordance with the Declaration 
of Helsinki (1996) and the International Conference on 
Harmonisation Guidelines for Good Clinical Practice (topic E6) 
and was approved by the State of Berlin ethics committee. Each 
participant gave written informed consent before any protocol-
speciﬁ  c activity or study entry. 
  Subjects 
  Men and women aged 18–70 years were eligible if they had 
had RA for ≥6 months as deﬁ  ned by the American College of 
Rheumatology criteria,  30   received methotrexate treatment for 
≥3 months (stable dose of 10–25 mg/week for ≥8 weeks) and 
had a Disease Activity Score 28-joint assessment (DAS28) ≤4.8 
(mild to moderate) for ≥3 months. Exclusion criteria included 
any form of arthritis other than RA, current or recent serious 
infection, signiﬁ  cant systemic illness or malignancy, neutrope-
nia, use of biological agents for RA within 6 months before the 
baseline visit and concomitant use of disease-modifying anti-
rheumatic drugs other than methotrexate.   
  Study  protocol 
  This was a randomised, double-blind, placebo-controlled, single-
dose-escalating study to evaluate the safety, tolerability, phar-
macokinetic and pharmacodynamic proﬁ  les of mavrilimumab in 
subjects with RA. Subjects were randomised to mavrilimumab 
or placebo cohorts by an interactive voice response system 
(Perceptive Informatics, Waltham, Massachusetts, USA). The 
study comprised six cohorts. Because mavrilimumab is an anti-
body to a cell surface receptor, cohort 1 included two unblinded 
subjects to evaluate the ﬁ  rst two mavrilimumab doses (0.01 and 
0.03 mg/kg, one subject each) and to monitor unpredictable side 
effects before proceeding to the double-blind, randomised arm 
of the study. No controls were assigned to cohort 1. Cohorts 2–6 
included six subjects randomised 5:1 to receive mavrilimumab 
or placebo, respectively. A safety review board examined the 
week 1 safety data for each dose cohort (upon completion of the 
ﬁ  rst week of follow-up) in combination with all available safety 
data from all subjects enrolled in the study.   
  Treatment 
  In addition to stable methotrexate treatment, subjects received a 
single, escalating intravenous dose of mavrilimumab (0.01, 0.03, 
0.1, 0.3, 1.0, 3.0 and 10.0 mg/kg) or placebo on study day 0. 
Infusions lasted ~1 h. Subjects were followed up for 24 weeks 
after infusion.   
  Outcome  measures 
  Safety  and  tolerability 
  Safety proﬁ  le evaluation included collection of adverse events 
(AEs) and serious AEs, haematology, blood chemistry labora-
tory results and vital signs from randomisation through study 
week 24. AEs were graded by severity and relationship to study 
drug. 
  Blood samples for chemistry, complete blood count with dif-
ferential and platelet counts, and pharmacokinetics and ex vivo 
pharmacodynamics of mavrilimumab as well as urine samples 
for urine analysis were collected before dosing, on study days 1, 
2 and 3, and then weekly through study week 24, except weeks 
16 and 20. Urine samples for pregnancy testing were collected 
before dosing and at weeks 4, 12 and 24. 
  The presence of anti-mavrilimumab antibodies in serum was 
determined using a validated bridging electrochemiluminescent 
immunoassay. Viral surveillance testing for Epstein–Barr virus 
and cytomegalovirus was conducted on study day −1 and at 
study week 6. Lung function tests, such as spirometry and dif-
fusing capacity of lung for carbon monoxide, were conducted at 
baseline and week 12 to assess for potential lung toxicities after 
mavrilimumab administration.   
  Pharmacokinetics  and  pharmacodynamics 
  Mavrilimumab concentrations were measured using a validated 
electrochemiluminescent method with a monoclonal anti-
idiotypic antibody as the capture reagent. Non-compartmental 
pharmacokinetic data analysis was performed using WinNonlin 
Professional (version 5.2; Pharsight, Mountain View, California, 
USA). The pharmacodynamic activity of mavrilimumab was 
assessed at baseline and at 4 and 336 h (2 weeks) after dosing 
in an ex vivo assay, in which the effect of mavrilimumab on 
GM-CSF-stimulated expression of suppressor of cytokine signal-
ling 3 (SOCS3) mRNA was investigated. This assay is described 
in the online supplemental methods.   
  Clinical  RA  assessments 
  Exploratory clinical assessments included DAS28 and its core 
components (tender and swollen joint counts, erythrocyte sedi-
mentation rate (ESR) or circulating C-reactive protein (CRP) and 
physician’s global assessment of disease activity); subject’s global 
assessment of disease activity, pain and fatigue using a visual ana-
logue scale; and subject’s assessment of physical function using 
the Health Assessment Questionnaire.  31   RA clinical assessments 
were undertaken at baseline, week 4 and week 12; ESR and CRP 
levels were monitored as part of the haematological evaluation at 
screening, days −1, 0, 1, 2 and 3, and weeks 1, 2, 3, 4, 5, 6, 8, 10, 
12 and 24. Exploratory subanalyses were based on subjects with 
either a baseline DAS28 >3.2 or circulating CRP levels >5 mg/l.     
  Statistical  analysis 
  Data were analysed by descriptive statistics. Exploratory suba-
nalyses of subjects with a DAS28 score >3.2 were conducted 
using a paired t test to compare scores at baseline and week 4. 
Subanalysis of subjects with CRP >5 mg/l was conducted using a 
repeated analysis of variance with Bonferroni-corrected p value. 
p < 0.05 indicated statistical signiﬁ   cance. All analyses were 
determined using GraphPad Prism Software (version 8.2 Prism; 
GraphPad Software, La Jolla, California, USA).     
  RESULTS 
  Subjects 
  Thirty-two subjects with mild to moderate RA were enrolled. 
All enrolled subjects completed all planned evaluations and 
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were included in the safety analyses. One subject (10.0 mg/  kg 
cohort) who experienced moderate face and neck urticaria 
  during infusion did not receive the full mavrilimumab dose 
and was excluded from the pharmacokinetic analysis. Twenty-
seven subjects were randomised to the mavrilimumab cohorts, 
and ﬁ  ve were randomised to placebo. Cohort 1 (n = 2) received 
open-label active medication (0.01 or 0.03 mg/kg). The remain-
ing subjects were randomised to receive 0.1, 0.3, 1.0, 3.0 and 
10.0 mavrilimumab (n = 5/cohort) or placebo (n = 1/cohort). 
  Table 1   shows subjects’ baseline demographic characteristics.     
    Safety and tolerability proﬁ  le 
  Adverse  events 
  Over the 6-month study period, 69 AEs were reported in 20 
mavrilimumab subjects (74%), and 13 were reported in four 
placebo subjects (80%). The most commonly reported AEs 
across cohorts were nasopharyngitis, headache, diarrhoea and 
back pain (  table 2  ). The majority of AEs were mild, and none 
resulted in study withdrawal. One subject (10.0 mg/kg mavrili-
mumab group) did not receive the full infusion owing to grade 
2 urticaria of the face and neck that occurred ~15 min after the 
infusion started. This event led to discontinuation of the infu-
sion. The event was resolved promptly, with no sequelae, after 
symptomatic treatment. No relationship was apparent between 
mavrilimumab dose and the severity or frequency of any AEs.   
  Eleven treatment-related AEs were reported. A total of six 
  treatment-related AEs were observed across the six mavri-
limumab cohorts, including one AE in the 10.0 mg/kg cohort 
(  urticaria), three AEs in the 0.3 mg/kg cohort (headache, migraine, 
nausea) and two AEs in the 0.1 mg/kg cohort (diarrhoea, periph-
eral oedema). No treatment-related AEs were reported in the 3.0 
or 1.0 mg/kg groups. Five treatment-related AEs in the placebo 
cohort included nausea, vomiting and headache (n = 1); paraes-
thesia (n = 1); and headache (n = 1). No abnormal haematol-
ogy was reported as an AE, and no clinically signiﬁ  cant changes 
in leucocyte, neutrophil or monocyte levels were observed 
between the placebo and mavrilimumab cohorts irrespective 
of dose (see online supplementary ﬁ  gure S1). No change was 
observed with lymphocytes (data not shown). No differences in 
lung function were seen (see online supplementary table S1).   
  Serious  AEs 
  Two non-treatment-related serious AEs were reported: one 
subject was hospitalised for bilateral inguinal hernia repair 
4 months after dosing (0.03 mg/kg cohort), and one subject 
(61-year-old woman, 3.0 mg/kg cohort) was reported to have 
 Table  1         Subject demographic characteristics at baseline   
 Parameter 
 Placebo 
(n = 5) 
 All  mavrilimumab 
(n = 27) 
 Mavrilimumab  (mg/kg) 
  0.01 (n = 1)    0.03 (n = 1)    0.1 (n = 5)    0.3 (n = 5)    1.0 (n = 5)    3.0 (n = 5)    10.0 (n = 5) 
No. of subjects who 
completed the study
5 2 7 1155555
Age (years) 53 ± 6.8 53 ± 10.4 67 33 47 ± 5.8 55 ± 4.3 46 ± 13.8 57 ± 6.1 58 ± 10.5
Gender, n
 Male 0 4 0101011
 Female 5 23 1054544
White race, n (%) 5 (100) 27 (100) 1 (100) 1 (100) 5 (100) 5 (100) 5 (100) 5 (100) 5 (100)
Methotrexate (mg/day) 14.0 ± 2.2 16 ± 3.2 20.0 15.0 16.0 ± 5.7 16.0 ± 2.2 16.0 ± 2.2 15.0 ± 3.5 16.0 ± 2.2
DAS28 3.79 ± 1.0 3.35 ± 0.9 4.35 3.46 3.08 ± 0.5 3.91 ± 0.4 3.58 ± 0.8 3.29 ± 1.4 2.69 ± 0.9
Tender joints 4 ± 3.6 3 ± 2.9 3 4 1 ± 1.0 4 ± 2.7 3 ± 3.3 3 ± 2.3 3 ± 4.7
Swollen joints 2 ± 1.5 1 ± 1.2 0 1 0 ± 0.0 1 ± 0.5 2 ± 2.5 1 ± 0.9 0 ± 0.5
CRP (mg/l) 5.7 ± 6.0 6.6 ± 9.4 47.8 4.1 4.7 ± 3.7 5.1 ± 3.3 6.4 ± 6.1 7.3 ± 7.4 1.7 ± 0.5
ESR (mm/h) 17.0 ± 7.5 18.0 ± 12.4 50.0 10.0 25.0 ± 13.2 18.0 ± 11.6 16.0 ± 3.6 19.0 ± 12.7 6.0 ± 1.6
Weight (kg) 73.9 ± 15.9 76.7 ± 16.7 85.6 86.1 66.1 ± 21.3 71.6 ± 14.4 82.0 ± 16.9 79.1 ± 18.8 80.7 ± 15.3
HAQ (score 0–3) 1.60 ± 0.41 1.61 ± 0.33 1.50 1.250 1.700 ± 0.29 1.775 ± 0.45 1.600 ± 0.14 1.525 ± 0.37 1.550 ± 0.44
      Medical history terms were classiﬁ  ed according to the terminology of the Medical Dictionary for Regulatory Activities (version 11). Values are mean ± SD unless otherwise noted.   
    CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment  Questionnaire.   
 Table  2      Incidence of adverse events by frequency (reported by more than one subject)   
Adverse event
Treatment group
Placebo (n = 5) Mavrilimumab  *   (n = 27)
No of AEs No (%) of subjects No of AEs No (%) of subjects
 Total   13   4  (80)   69   20  (74) 
 Nasopharyngitis   3   2  (40)   11   10  (37) 
 Headache   2   2  (40)   7   5  (19) 
 Diarrhoea   1   1  (20)   5   5  (19) 
 Back  pain   1   1  (20)   4   4  (15) 
 Peripheral  oedema   0   0   3   3  (11) 
 Nausea   1   1  (20)   2   2  (7) 
 Bronchitis   0   0   2   2  (7) 
 Dizziness   0   0   2   2  (7) 
 Hypertension   0   0   2   2  (7) 
 Pharyngolaryngeal  pain   0   0   2   2  (7) 
 Vomiting   1   1  (20)   1   1  (4) 
      *      All doses.   AEs were classiﬁ  ed according to the terminology of the Medical Dictionary for Regulatory Activities (version 11).   
   AE,  adverse  event.    
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carcinoma of the right breast at the week 8 visit. The subject had 
detected a lump in her right breast before randomisation but did 
not report it to her doctor until 3 days after receiving the study 
drug. No clinical viral infection events were reported, and no 
subject experienced clinically signiﬁ  cant laboratory abnormali-
ties or changes in vital signs during the study. No subjects devel-
oped anti-mavrilimumab antibodies during the study and safety 
follow-up periods.     
  Pharmacokinetics 
  The mean pharmacokinetic proﬁ  les of mavrilimumab after a 
  single intravenous dose are shown in   ﬁ  gure 1  . All pharmaco-
kinetic observations at the last visit (day 168) were below the 
assay limit of measurement. Non-compartmental pharmaco-
kinetic parameters are summarised in   table 3  .       
Although there was a dose-proportional increase in maximum 
observed concentration, the increase in area under the curve was 
more than dose proportional. Systemic clearance decreased from 
88.8 to 3.15 ml/kg/day when the dose was increased from 0.01 
to 10.0 mg/kg. Accordingly, the half-life was more prolonged 
in higher-dose cohorts. At the highest dose level investigated 
(10.0 mg/kg), the elimination half-life of mavrilimumab was 
~15 days. 
  The distribution volume of mavrilimumab could not be 
accurately determined because the pharmacokinetics of mavri-
limumab was not linear at lower dose levels. However, the esti-
mated steady-state volume of distribution was slightly greater 
than the serum volume in subjects receiving the 10.0 mg/kg 
dose.   
  Pharmacodynamics 
  Quantitative RT-PCR showed a three- to fourfold increase (mean 
3.274 ± 1.42; 95% CI 2.42 to 4.13) in the levels of SOCS3 mRNA 
transcript compared with the levels of 18S mRNA transcript in 
ex vivo stimulated leucocytes from the placebo and 0.3, 1.0 and 
3.0 mg/kg mavrilimumab cohorts before dosing. Four hours 
after dosing, the induction of SOCS3 mRNA by GM-CSF was 
  inhibited by 90% and 84% in the 1.0 and 3.0 mg/kg cohorts, 
respectively (p ≤ 0.05). This effect was sustained for 336 h 
(2 weeks) in the 1.0 mg/kg cohort (p ≤ 0.05; 47% reduction), 
with a trend to suppression in the 3.0 mg/kg cohort that was 
not statistically signiﬁ  cant (p > 0.05). No signiﬁ  cant inhibition of 
SOCS3 expression at 4 and 336 h was seen in either the placebo 
or 0.3 mg/kg cohort (  ﬁ  gure 2  ).     
  Clinical  activity 
  Subjects had mild to moderate disease activity at baseline, with 
a mean DAS28 of 3.79 ± 1.0 and 3.35 ± 0.9 in the placebo and 
mavrilimumab cohorts, respectively. The majority (63%) had 
normal acute phase reactants at baseline. No signiﬁ  cant change 
 Figure  1         Mean pharmacokinetic proﬁ  les of mavrilimumab (formerly known as CAM-3001) after a single intravenous dose in subjects with mild 
to moderate rheumatoid arthritis. Error bars represent SEM. Pharmacokinetic observations from the subject in the 10.0 mg/kg cohort who received 
partial infusion were excluded from mean concentration calculations. LLOQ, lower limit of quantiﬁ  cation.       
 Table  3      Non-compartmental pharmacokinetic parameters of mavrilimumab in subjects with mild to moderate rheumatoid arthritis   
 Pharmacokinetic 
parameter 
  Mavrilimumab dose (mg/kg) 
  0.01 (n = 1)    0.03 (n = 1)    0.1 (n = 5)    0.3 (n = 5)    1.0 (n = 5)    3.0 (n = 5)    10.0 (n = 4) 
C  max   (µg/ml) 0.241 0.550 2.95 (0.87) 6.72 (1.43) 26.8 (4.69) 81.4 (23.6) 373 (38)
AUC  inf   (µg·day/ml) 0.113 0.781 5.01 (1.72) 25.4 (9.1) 147 (42) 706 (429) 3200 (290)
CL (ml/kg/day) 88.8 38.4 21.6 (6.1) 13.1 (4.6) 7.23 (2.07) 5.19 (2.06) 3.15 (0.31)
t  1/2   (day) 1.51 2.13 1.81 (0.59) 2.55 (0.21) 4.78 (0.66) 7.59 (1.83) 15.1 (3.6)
      Parameter values are shown as mean (SD) except for the 0.01 mg/kg and 0.03 mg/kg dose levels. Data from the subject who received partial infusion in the 10.0 mg/kg cohort were 
excluded from the analysis.   
  AUC inf  , area under the concentration–time curve extrapolated to inﬁ  nity; CL, systemic clearance; C  max  , maximum observed concentration; t  1/2 ,  elimination  half-life.   
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in DAS28 score between baseline, week 4 and week 12 was 
observed in the mavrilimumab cohorts (  ﬁ  gure 3A  ). Exploratory 
subanalyses showed that, of subjects exposed to mavrilimumab 
with DAS28 >2.6 at baseline, 33% (7/21) achieved a DAS28 
remission (<2.6) at week 4. In addition, subanalysis of sub-
jects receiving mavrilimumab with moderate disease activity 
(baseline DAS28 >3.2) demonstrated a statistically signiﬁ  cant 
reduction in DAS28 score at week 4 compared with controls 
(  ﬁ  gure  3B  ). Systemic inﬂ   ammation was monitored by CRP 
levels and ESR. Consistent with clinical score, there was no 
signiﬁ  cant change in CRP levels in response to mavrilimumab 
(  ﬁ  gure 3C  ); however, a trend towards a reduction was seen with 
mavrilimumab 0.1, 0.3, 1.0 and 3.0 mg/kg. To investigate this, a 
post hoc analysis was conducted for all subjects with elevated 
baseline CRP levels (>5 mg/l). In mavrilimumab subjects with 
elevated CRP (>5 mg/l) at baseline, mean CRP levels were sig-
niﬁ  cantly reduced for 4 weeks when compared with baseline 
(  ﬁ  gure 3D  ). CRP levels for these subjects returned to baseline by 
week 12. Furthermore, of the 10 mavrilimumab subjects with 
elevated (≥20 mm/h) ESR at baseline, 90% showed normalisa-
tion of ESR at least once during the ﬁ  rst 4 weeks after dosing.
      At study week 4, mean changes from baseline in subjects’ 
global assessments of RA and fatigue (visual analogue scale) were 
reductions of 20% and 1%, respectively, in the mavrilimumab 
cohorts. Subjects’ global assessment of pain and physicians’ 
assessment of RA were only assessed at the screening visit, with 
no   discernible differences in mean scores between cohorts.     
  DISCUSSION 
  There is increased awareness that aggressive treatment of RA 
should be started early to achieve remission and arrest radio-
graphic progression.  32   Furthermore, new biological treatments 
targeting B and T cells or soluble cytokines such as TNFα, IL-1 
or IL-6 are available and have further advanced the treatment of 
RA. However, a substantial number of subjects do not respond 
(primary non-responders) or experience a loss of efﬁ  cacy after a 
primary response (secondary non-responders). While monitor-
ing can help to identify non-responders early and allow switch-
ing to another treatment, the causes of non-response or loss of 
response remain, in most cases, elusive. Although it is possible 
that the clinical manifestations of RA may be driven by different 
pathways in different subjects, the multifactorial nature of the 
disease has made identiﬁ  cation of robust biomarkers challeng-
ing, thus highlighting a signiﬁ  cant unmet need.  33    –    35   In this small 
phase I study, mavrilimumab demonstrated an adequate safety 
proﬁ  le when administered as a single, escalating intravenous 
dose of 0.01–10.0 mg/kg in subjects with RA. Reported AEs 
were mostly mild and similar between the mavrilimumab and 
placebo cohorts. One treatment-related moderate event of urti-
caria was reported (10.0 mg/kg cohort), which led to early termi-
nation of the infusion. The event was treated symptomatically, 
resolved on the same day, and the subject remained in the study. 
This type of reaction has been observed as a common feature of 
monoclonal antibody infusion  36   and is typically related to the 
infusion rate and antibody concentration. No subject withdrew 
from the study owing to an AE or for any other reason. 
  Antibodies against cell membrane-associated antigens are 
usually subject to the target-mediated clearance, or the antigen 
sink effect.  37    –    40   There are two major elimination pathways for 
mavrilimumab: intrinsic clearance by the reticuloendothelial sys-
tem in the same way as that for an endogenous IgG, and elimi-
nation by the target antigen receptor (GM-CSFR-α–mediated 
clearance). At low serum concentrations, the antigen sink domi-
nates and mavrilimumab had a short elimination half-life. When 
the antigen sink is saturated, the elimination of mavrilimumab 
approximates that of an endogenous IgG, with a more prolonged 
elimination half-life. Consistent with previously reported antire-
ceptor antibodies,  38     41    –    44   mavrilimumab pharmacokinetics was 
non-linear at low doses. From the non-compartmental analysis, 
the systemic clearance of mavrilimumab approached the intrin-
sic clearance of endogenous IgG by the reticuloendothelial sys-
tem at doses >1.0 mg/kg, suggesting saturation of the antigen 
sink (full GM-CSFR-α occupancy) at higher dose levels. Once 
 Figure  2     Effect of mavrilimumab on suppressor of cytokine signalling 3 (SOCS3) mRNA transcript levels induced by granulocyte-macrophage 
colony-stimulating factor ex vivo from peripheral blood leucocytes of subjects with mild to moderate rheumatoid arthritis. Data are presented as 
mean (SE). Asterisks indicate a signiﬁ  cant change (*p<0.05) in comparison with predose samples within the same cohort; ns, not  signiﬁ   cant.    
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saturated, the pharmacokinetics of mavrilimumab ranged from 
4.78 to 15.1 days between 1.0 and 10.0 mg/kg, equivalent to the 
pharmacokinetics of currently approved antibody treatments 
for RA, such as adalimumab (0.25–5.0 mg/kg intravenous doses; 
apparent terminal half-life = 15–19 days)  45   and tocilizumab 
(8 mg/kg intravenous dose; half-life = 10 days).  46   
  The pharmacodynamics of mavrilimumab supports these 
pharmacokinetic observations. The ex vivo assay demonstrated 
a signiﬁ  cant inhibition of GM-CSF-induced SOCS3 expression 
4 h after dosing in peripheral white blood cells from subjects 
in the 1.0 and 3.0 mg/kg cohorts, but not the 0.3 mg/kg cohort, 
consistent with full receptor occupancy as predicted from non-
compartmental analysis. Furthermore, this effect appeared to be 
sustained for 2 weeks after dosing even though the 3.0 mg/  kg 
cohort did not achieve signiﬁ  cance. Since no additional data 
were collected after 2 weeks of dosing, the duration of receptor 
occupancy is unknown. 
  Because this was a phase I study designed to evaluate the 
safety and tolerability proﬁ  le of mavrilimumab, clinical activity 
was not formally determined. This was reﬂ  ected in the fact that 
63% of subjects had normal acute phase reactants at baseline; 
however, post hoc analyses of subjects with elevated baseline 
CRP (>5 mg/l) and ESR (>20 mm/h) showed a reduction of these 
markers at least once within the ﬁ  rst 4 weeks after mavrili-
mumab administration. Recombinant GM-CSF has been shown 
to increase both systemic IL-6 levels and circulating acute phase 
response proteins, such as CRP and serum amyloid A, and to 
exacerbate arthritis in neutropenic subjects.  24     25   Conversely, the 
observation that this antibody was able to reduce CRP levels is 
consistent with the hypothesised mechanism of action of mavri-
limumab. Moreover, exploratory subanalyses of pharmacologi-
cal activity demonstrated positive trends of mavrilimumab on 
RA signs and symptoms up to 4 weeks after a single infusion 
for subjects who had moderate disease activity (DAS28 >3.2). 
Additionally, a subset of subjects in the study with moderate dis-
ease activity experienced remission as deﬁ  ned by a DAS28 <2.6. 
While these preliminary observations are encouraging, this 
study was not designed or powered to demonstrate efﬁ  cacy; 
therefore, these results should be interpreted with caution. 
  This is the ﬁ  rst-in-human study of a monoclonal antibody 
targeting the GM-CSF pathway in RA. In this study, mavrili-
mumab given as a single, escalating intravenous dose (0.01–
10.0 mg/kg) had an adequate safety and tolerability proﬁ  le 
in subjects with mild to moderate RA. The pharmacokinetics 
 Figure  3        (A) Effect of mavrilimumab (formerly known as CAM-3001) on Disease Activity Score 28-joint assessment (DAS28) levels at baseline, 
week 4 and week 12. Data are presented as the mean (SD) for each visit. (B) Effect of mavrilimumab on DAS28 levels within the ﬁ  rst 4 weeks after 
a single intravenous dose in subjects with moderate disease (DAS28 >3.2 at baseline). (C) Effect of mavrilimumab on C-reactive protein (CRP) level 
at baseline (week 0), week 2 and week 4. Data are presented as the mean (SD) for each visit. (D) Effect of mavrilimumab on CRP level within the 
ﬁ  rst 4 weeks after a single intravenous dose in subjects with mild rheumatoid arthritis who had elevated (>5 mg/l) CRP levels at baseline. Legend: 
placebo (◊) and mavrilimumab 0.1 mg/kg (▲), 0.3 mg/kg (●), 1.0 mg/kg (■), 3.0 mg/kg (○) and 10.0 mg/kg (∆).    
05_annrheumdis146225.indd   1547 05_annrheumdis146225.indd   1547 7/28/2011   5:41:20 PM 7/28/2011   5:41:20 PMExtended report
Ann Rheum Dis 2011;70:1542–1549. doi:10.1136/ard.2010.146225 1548
was consistent for an antibody to a cell surface receptor and 
suggested full GM-CSFR-α occupancy at doses ≥1.0 mg/kg. 
Additionally, subjects with elevated baseline CRP and ESR 
showed a trend towards a reduction of circulating CRP levels 
or normalisation of ESR at least once within the ﬁ  rst 4 weeks 
after administration. 
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